203 related articles for article (PubMed ID: 25939552)
1. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
Zhao J; Cao Y; Jusko WJ
Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
[TBL] [Abstract][Full Text] [Related]
2. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
3. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
[TBL] [Abstract][Full Text] [Related]
4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
5. Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.
Song D; Jusko WJ
Biopharm Drug Dispos; 2021 May; 42(5):191-203. PubMed ID: 33638217
[TBL] [Abstract][Full Text] [Related]
6. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
[TBL] [Abstract][Full Text] [Related]
7. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
8. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
9. Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species.
Jeong YS; Jusko WJ
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34200427
[TBL] [Abstract][Full Text] [Related]
10. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
11. Applications of minimal physiologically-based pharmacokinetic models.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):711-23. PubMed ID: 23179857
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Various Approaches to Translate Non-Linear Pharmacokinetics of Monoclonal Antibodies from Cynomolgus Monkey to Human.
Singh R; Moreno M; Stanimirovic D
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):555-567. PubMed ID: 34120326
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
14. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
[TBL] [Abstract][Full Text] [Related]
15. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
17. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
18. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
19. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
20. An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.
Chadha GS; Morris ME
AAPS J; 2015 Nov; 17(6):1464-74. PubMed ID: 26276217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]